2 results
Approved WMORecruiting
The primary objective of RIN-PF-303 is to evaluate superiority of inhaled treprostinil against placebo for the annual rate of change in absolute forced vital capacity (FVC) from baseline to Week 52.
An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis
To evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with IPF.